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Abstract
BACKGROUND: The National Institute on Aging and 
Alzheimer’s Association (NIA-AA) have proposed a new 
Research Framework: Towards a biological definition of 
Alzheimer’s disease, which uses a three-biomarker construct: 
Aß-amyloid, tau and neurodegeneration AT(N), to generate a 
biomarker based definition of Alzheimer’s disease.
OBJECTIVES: To stratify AIBL participants using the new 
NIA-AA Research Framework using cerebrospinal fluid (CSF) 
biomarkers. To evaluate the clinical and cognitive profiles of 
the different groups resultant from the AT(N) stratification. 
To compare the findings to those that result from stratification 
using two-biomarker construct criteria (AT and/or A(N)).   
DESIGN: Individuals were classified as being positive or 
negative for each of the A, T, and (N) categories and then 
assigned to the appropriate AT(N) combinatorial group: A-T-
(N)-; A+T-(N)-; A+T+(N)-; A+T-(N)+; A+T+(N)+; A-T+(N)-; 
A-T-(N)+; A-T+(N)+. In line with the NIA-AA research 
framework, these eight AT(N) groups were then collapsed 
into four main groups of interest (normal AD biomarkers, AD 
pathologic change, AD and non-AD pathologic change) and 
the respective clinical and cognitive trajectories over 4.5 years 
for each group were assessed. In two sensitivity analyses the 
methods were replicated after assigning individuals to four 
groups based on being positive or negative for AT biomarkers 
as well as A(N) biomarkers.
SETTING: Two study centers in Melbourne (Victoria) and Perth 
(Western Australia), Australia recruited MCI individuals and 
individuals with AD from primary care physicians or tertiary 
memory disorder clinics. Cognitively healthy, elderly NCs were 
recruited through advertisement or via spouses of participants 
in the study.
PARTICIPANTS: One-hundred and forty NC, 33 MCI 
participants, and 27 participants with AD from the AIBL study 
who had undergone CSF evaluation using Elecsys® assays.
INTERVENTION (if any): Not applicable.
MEASUREMENTS: Three CSF biomarkers, namely amyloid 
β1-42, phosphorylated tau181, and total tau, were measured 
to provide the AT(N) classifications. Clinical and cognitive 
trajectories were evaluated using the AIBL Preclinical 
Alzheimer Cognitive Composite (AIBL-PACC), a verbal 
episodic memory composite, an executive function composite, 
California Verbal Learning Test – Second Edition; Long-Delay 
Free Recall, Mini-Mental State Examination, and Clinical 
Dementia Rating Sum of Boxes scores.
RESULTS: Thirty-eight percent of the elderly NCs had no 
evidence of abnormal AD biomarkers, whereas 33% had 
biomarker levels consistent with AD or AD pathologic change, 
and 29% had evidence of non-AD biomarker change. Among 
NC participants, those with biomarker evidence of AD 
pathology tended to perform worse on cognitive outcome 
assessments than other biomarker groups. Approximately 
three in four participants with MCI or AD had biomarker levels 
consistent with the research framework’s definition of AD or 
AD pathologic change. For MCI participants, a decrease in 
AIBL-PACC scores was observed with increasing abnormal 
biomarkers; and increased abnormal biomarkers were also 
associated with increased rates of decline across some cognitive 
measures.
CONCLUSIONS: Increasing biomarker abnormality appears 
to be associated with worse cognitive trajectories. The 
implementation of biomarker classifications could help better 
characterize prognosis in clinical practice and identify those 
at-risk individuals more likely to clinically progress, for their 
inclusion in future therapeutic trials.
Key words: Alzheimer’s disease, biomarkers, progression, longitudinal. 
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease characterized by neurodegeneration, synaptic loss, and the 
accumulation of extracellular-amyloid plaques and tau 
intracellular neurofibrillary tangles (1, 2). Several key 
imaging and cerebrospinal fluid (CSF) biomarkers have 
been identified in AD (3, 4). Deposition of beta-amyloid 
(Aβ-amyloid) plaques is one of the most important 
pathologic hallmarks of AD and is widely thought to 
be the initiating and primary driver of disease (amyloid 
hypothesis) (5, 6). Measures of Aβ-amyloid include 
© The Author(s)
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amyloid imaging with positron emission tomography 
(PET) as well as CSF Aβ1-42, and studies have shown 
that these markers may be detectable over a decade 
before symptom onset (6, 7). Neurodegeneration and 
synaptic loss are also apparent prior to symptom onset, 
and may be visible on brain magnetic resonance imaging 
(MRI) as structural atrophy in regions consistent with 
AD (3). Other methods of assessing neurodegeneration 
include fluorodeoxyglucose [FDG]-PET, which measures 
brain metabolism as an indicator of synaptic activity 
(8, 9) and CSF total tau (t-tau), which is also indicative 
of synaptic loss and neurodegeneration (4, 10). Finally, 
tau pathology may be assessed using tau PET or CSF 
phosphorylated tau (p-tau), which has shown utility for 
predicting progression from mild cognitive impairment 
(MCI) to AD dementia as well as differentiating AD from 
other forms of dementia (3, 4, 11, 12).  
Based on these biomarkers of Aβ-amyloid (CSF Aβ1–
42), neurodegeneration (t-tau) and tau pathology (p-tau), 
various constructs have been developed to accurately 
identify individuals in the earliest (pre-symptomatic) 
stages of disease who are likely to progress to MCI and 
AD. Initial diagnostic research criteria developed by the 
National Institute on Aging and Alzheimer’s Association 
(NIA-AA) classified individuals with evidence of 
Aβ-amyloid pathology (i.e., abnormal Aβ-amyloid PET 
and CSF Aβ-amyloid) into three stages of preclinical AD 
based on the presence or absence of markers of neuronal 
injury (i.e., FDG-PET, structural MRI, or measures of 
tau) and evidence of subtle cognitive change (13). The 
criteria were further expanded to include two additional 
categories for cognitively normal individuals, including 
those with no biomarkers of AD (i.e., normal Aβ-amyloid, 
neurodegeneration, and tau) and those without evidence 
of Aβ-amyloid pathology but who are positive for 
other markers of neuronal injury, also referred to as 
suspected non-AD pathophysiology (SNAP) (14). 
These classifications were able to characterize 97% of 
cognitively normal individuals from a population-
based sample (14) and have been shown to correlate 
with the cognitive trajectories and disease progression of 
individuals over time (15, 16). 
While previous iterations of the NIA-AA criteria 
were based on a two-marker construct using evidence 
of Aβ-amyloid pathology and neurodegeneration as a 
single category, it is thought that segregating measures 
of pathologic tau (i.e., tau PET, CSF p-tau) from other 
markers of neuronal injury may help to better distinguish 
AD-related pathology from other neurodegenerative 
conditions (3). The recent NIA-AA Research Framework: 
Towards a biological definition of Alzheimer’s disease 
(4) is therefore based on a three-marker construct. The 
recent framework uses normal (-) or abnormal (+) levels 
of Aβ-amyloid deposition (“A”), pathologic tau (“T”), 
and neurodegeneration (“(N)”) as constructs to create 
the AT(N) classification system. In this contribution, we 
interrogated the AT(N) classification system to improve 
understanding for its implementation and applicability 
in characterizing and understanding the pathogenesis 
of AD. Firstly, we apply the AT(N) classification system 
to CSF biomarkers from well-characterized participants 
in the longitudinal Australian Imaging, Biomarker & 
Lifestyle (AIBL) Flagship Study of Ageing. Secondly, we 
describe the long-term clinical and cognitive trajectories 
of AIBL elderly cognitively normal controls (NCs) as 
well as AIBL MCI individuals, using the three-marker 
construct.
 
Methods
The AIBL cohort
The AIBL cohort study of aging combines data 
from neuroimaging, biomarkers, lifestyle, clinical, and 
neuropsychological assessments. Two study centers in 
Melbourne (Victoria) and Perth (Western Australia), 
Australia recruited individuals with MCI and with 
AD from primary care physicians or tertiary memory 
disorders clinics. Cognitively healthy NC participants 
were recruited through advertisement or via spouses 
of participants in the study. Exclusion criteria included 
a history of non-AD dementia, Parkinson’s disease, 
schizophrenia, bipolar disorder, current depression, 
cancer in the past 2 years (with the exception of basal-
cell skin carcinoma), symptomatic stroke, uncontrolled 
diabetes, or current regular alcohol use. Between 
November 3, 2006, and October 30, 2008, AIBL recruited 
1112 eligible volunteers who were at least 60 years old 
and fluent in English. Full details on the study design 
and inclusion criteria have been reported elsewhere 
(17). An enrichment cohort of 86 participants with AD, 
124 MCI participants, and 389 NC participants were 
recruited by AIBL between March 30, 2011, and June 29, 
2015. At baseline, the AIBL study participants had an 
average age of 72 years, 58% were female, and 36% were 
Apolipoprotein E (APOE) ε4 carriers. APOE ε4 carriage 
was determined as previously described (18). Two 
hundred AIBL participants (140 NC, 33 MCI and 27 AD) 
with a mean age of 73 (50% Males) who had undergone 
lumbar puncture were included in the current study.  
Assessment of CSF biomarkers
Lumbar puncture was used to collect CSF from 200 
AIBL participants in the morning after overnight fasting, 
with a protocol aligned to the Alzheimer’s Biomarkers 
Standardization Initiative (ABSI). Lumbar puncture was 
performed in the sitting position using a strictly aseptic 
technique and gravity drip collection. CSF was collected 
into a polypropylene tube and placed on ice prior to 
centrifugation (2000 ×g at 4°C for 10 minutes), and the 
supernatant was transferred to a second polypropylene 
tube and gently inverted. Samples were aliquoted 
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(500 μL) into Nunc cryobank polypropylene tubes 
(NUN374088) and stored in liquid nitrogen vapor tanks 
within 1 hour (kept on dry ice prior to storage) and 
only thawed once, immediately before analysis. CSF 
levels of Aβ1-42, t-tau, and p-tau were measured by 
electrochemiluminescence Elecsys® immunoassay (Roche 
Diagnostics, Penzberg, Germany) that uses a quantitative 
sandwich principle. Levels were measured using the 
Roche cobas® e601 analyzer (Roche Diagnostics) with a 
total assay duration of 18 minutes.
Application of  the  NIA-AA Research 
Framework
The NIA-AA Research Framework (4), details 
grouping of individuals based on AT(N) criteria, 
where: ‘A’ represents Aβ-amyloid or associated 
pathologic state—here ‘A’ is defined using CSF Aβ1-
42; ‘T’ represents aggregated tau (neurofibrillary 
tangles) or associated pathologic state—in this current 
study ‘T’ is defined using CSF p-tau; ‘(N)’ represents 
neurodegeneration or neuronal injury—here ‘(N)’ 
is defined using CSF t-tau. Individuals were classified 
as being positive or negative for each of the A, T, and 
(N) criteria. A+ was defined as having a CSF Aβ1-42 
level ≤1054.00pg/mL and A- as having a CSF Aβ1-42 
level >1054.00 pg/mL. T+ was defined as having a CSF 
p-tau level ≥21.34 pg/mL and T- as having a CSF p-tau 
level <21.34 pg/mL. (N)+ was defined as having a CSF 
t-tau level ≥212.60 pg/mL and T- as having a CSF p-tau 
level <212.60 pg/mL. Individuals were then classified 
as belonging to one of the eight AT(N) combinatorial 
groups: A-T-(N)-; A+T-(N)-; A+T+(N)-; A+T-(N)+; 
A+T+(N)+; A-T+(N)-; A-T-(N)+; A-T+(N)+. In line with 
the NIA-AA Research Framework (4), the eight AT(N) 
groups were collapsed into four main groups of interest: 
those with normal AD biomarkers (A-T-(N)-), those 
with non-AD pathologic change (A-T+(N)-; A-T+(N)+; 
A-T+(N)-), those with AD pathologic change (A+T-(N)-; 
A+T-(N)+), and those with AD (A+T+(N)-; A+T+(N)+).
Cognitive markers
A l l  p a r t i c i p a n t s  u n d e r w e n t  e x t e n s i v e 
neuropsychological testing, as previously described 
(17). Briefly, the tests comprising the AIBL clinical and 
neuropsychological battery were selected to cover the 
main domains of cognition affected by AD and other 
dementias, and are all internationally recognized as 
having good reliability and validity. The full battery 
comprised: the Clinical Dementia Rating (CDR) Scale, 
Mini-Mental State Examination (MMSE) (19), Clock-
Drawing Test, California Verbal Learning Test – Second 
Edition (CVLT-II) (20), Logical Memory (LM) I and II 
(Wechsler Memory Scale [WMS]-III; Story A only) (21-23), 
Delis–Kaplan Executive Function System (D-KEFS) verbal 
fluency (24), 30-item Boston Naming Test (BNT) (25), 
the Stroop Test (Victoria version) (22), the Rey Complex 
Figure Test (RCFT) (26), Digit Span and Digit Symbol-
Coding subtests of the Wechsler Adult Intelligence Scale 
– Third Edition (WAIS–III) (27), the Wechsler Test of 
Adult Reading (WTAR) (28), the Hospital Anxiety and 
Depression Scale (HADS), and the Geriatric Depression 
Scale (GDS).
Clinical and cognitive trajectories were evaluated using 
the AIBL-Preclinical Alzheimer Cognitive Composite 
(AIBL-PACC) (29), a verbal episodic memory composite, 
an executive function composite (30), CVLT-II Long-
Delay Free Recall (CVLT-II LDFR), MMSE, and CDR 
Sum of Boxes (CDR SoB) measures. The AIBL-PACC was 
constructed by summing Z-score measures of CVLT-
II LDFR, LM-II, MMSE, and Digit Symbol-Coding. 
The verbal episodic memory composite was created 
from Z-scores of CVLT-II LDFR, CVLT-II recognition 
false positives, and LM-II, and the executive function 
composite was generated from Z-scores of D-KEFS letter 
fluency and category switching totals as well as the 
colors/dots interference measure from the Stroop Test 
(Victoria version). 
Analysis
Demographic information was assessed across 
clinical classifications for 200 AIBL participants who had 
undergone CSF evaluation. Participants were classified 
into one of eight categories based on the three-construct 
model of AT(N) in the NIA-AA Research Framework. 
The prevalence of the AT(N) groups was assessed across 
the clinical classification groups. The eight AT(N) groups 
were then collapsed into four main groups of interest: 
those with normal AD biomarkers, those with non-AD 
pathologic change, those with AD pathologic change, 
and those with AD. Baseline cognitive performance was 
assessed across these four groups within the NC and MCI 
clinical classification groups using boxplots and one-way 
t-tests. Longitudinal change in cognitive performance 
over time, separately for the NC and MCI, was assessed 
using boxplots and one-way t-tests of the random slopes 
obtained from linear mixed-effect models. In the linear 
mixed-effect models, the cognitive measure represented 
the dependent variable; age, sex, and APOE ε4 status 
were included as interacting independent factors and 
time since CSF evaluation was included as a random 
factor. The dependent variable was evaluated every 18 
months for a mean follow-up of 4.5 years. The number of 
participants progressing towards more advanced disease 
(i.e., NC to MCI/AD and MCI to AD) within each of 
these four groups was also evaluated using descriptive 
statistics, due to the small number of conversions more 
sophisticated analyses such as Cox proportional hazards 
analyses could not be undertaken.
251
Sensitivity Analysis I
Participants were assigned to one of four groups (A-T-; 
A+T-; A-T+; A+T+) based on their CSF Aβ1-42 and p-tau 
levels as described above. Baseline cognitive performance 
was assessed across these four AT groups within each 
clinical classification group using boxplots and one-way 
t-tests. Longitudinal change in cognitive performance 
over time was assessed using boxplots and one-way 
t-tests of the random slopes obtained from linear mixed-
effect models. In the linear mixed-effect models, the 
cognitive measure represented the dependent variable; 
age, sex, and APOE ε4 status were included as interacting 
independent factors and time since CSF evaluation was 
included as a random factor.
Sensitivity Analysis II
Participants were assigned to one of four groups 
(A-N-; A+N-; A-N+; A+N+) based on their CSF Aβ1-42 
and t-tau levels as described above. Baseline cognitive 
performance was assessed across these four A(N) groups 
within each clinical classification group using boxplots 
and one-way t-tests. Longitudinal change in cognitive 
performance over time was assessed using boxplots and 
one-way t-tests of the random slopes obtained from 
linear mixed-effect models. In the linear mixed-effect 
models, the cognitive measure represented the dependent 
variable; age, sex, and APOE ε4 status were included 
as interacting independent factors and time since CSF 
evaluation was included as a random factor.
Results
Demographics
The majority of participants (140/200) were cognitively 
healthy (NC) and the remaining comprised MCI or AD 
(n=33 and n=27, respectively) (Table 1). There was a 
higher prevalence of males in the MCI and AD samples 
compared to the NC sample. Reported ages at baseline 
did not differ across the three samples (averaging around 
73 years). The NC participants had a higher level of 
education and had fewer APOE ε4 carriers. The mean 
duration of follow-up for all participants was 4.54 years. 
AD, Alzheimer’s disease; MCI, mild cognitive impairment
Table 1. Demographics
Metric AD MCI NC Total
Number of participants 27 33 140 200
Males, n (%) 15 (55.6) 23 (69.7) 61 (43.6) 99 (49.5)
Mean age, years (SD) 73.77 (8.2) 73.1 (6.5) 72.15 (6.0) 72.54 (6.3)
Years of education, n (%)
<9 4 (16.7) 5 (15.2) 6 (4.3) 15 (7.6)
9-12 10 (41.7) 15 (45.5) 53 (37.9) 78 (39.6)
13-15 5 (20.8) 5 (15.2) 25 (17.9) 35 (17.8)
>15 5 (20.8) 8 (24.2) 56 (40.0) 69 (35.0)
APOE ε4 carriers, n (%) 12 (44.4) 11 (33.3) 31 (22.1) 54 (27)
Mean duration of follow-up, years (SD) 2.78 (2.0) 3.56 (2.3) 5.14 (2.7) 4.54 (2.7)
AD, Alzheimer’s disease; APOE, Apolipoprotein E; MCI, mild cognitive impairment; NC, normal control; SD, standard deviation.
Figure 1. Prevalence of the AT(N) groups across clinical 
classifications
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Prevalence of AT(N) groups
The prevalence of each of the eight AT(N) classifications 
within the AIBL NC, MCI, and AD samples are given in 
Figure 1. The highest proportion of NC participants (38%) 
had normal AD biomarkers; 13% had AD pathologic 
change, 20% have AD, and 29% had non-AD pathologic 
change. In the MCI and AD samples, 75% and 70% of 
participants had AD pathologic change, respectively.
Cross-sectional cognitive performance in NC
In general, NC participants with biomarkers consistent 
with AD performed the worst on the cognitive composite 
markers and MMSE (Figure 2A‒C and E). Differences 
were not observed for CDR SoB with all NCs scoring 0 
on this test (Figure 2D). The NC participants with normal 
AD biomarkers had the lowest scores on the CVLT-II 
LDFR (Figure 2F). In general, within the NC sample 
those classified as having non-AD pathologic change 
had similar scores to those with normal AD biomarkers. 
Regarding the sensitivity analyses, The A+T+ group had 
significantly (p=0.03) lower baseline scores for AIBL-
PACC in comparison to the A-T- group and the A+T+ 
group had significantly lower baseline scores for the 
Verbal Episodic Memory composite than the A-T+ group. 
Also, the A+N+ group had significantly lower baseline 
scores for the Verbal Episodic Memory composite than 
the A-N+ group. No other differences were observed 
in the sensitivity analyses of differences in the NC at 
baseline. 
Cross-sectional cognitive performance in MCI
For MCI participants there was a decrease in 
performance from those with normal AD biomarkers, to 
those with AD pathologic change and then AD for the 
AIBL-PACC (Figure 3A). This trend was not observed in 
the other five clinical and cognitive markers considered 
(Figure 3B–F). No baseline differences were obsevered for 
the MCI in the sensitivity analyses.
Longitudinal change in cognitive performance 
For both the NC and MCI participants, systematic 
differences were not observed in the rates of decline for 
the four groups considered (Supplementary Figures 1 
and 2). No differences were observed in the sensitivity 
analyses.
Figure 2. Cross-sectional performance on the six cognitive measures (A: AIBL-PACC; B: Verbal Episodic Memory; C: 
Executive Function; D: CDR Sum of Boxes; E: MMSE; F: CVLT-II LDFR) for the four contracted AT(N) groups in NC 
AD, Alzheimer’s disease; AIBL-PACC, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing – Preclinical Alzheimer Cognitive Composite; CDR, Clinical 
Dementia Rating; CVLT-II LDFR, California Verbal Learning Test – Second Edition; Long-Delay Free Recall; MMSE, Mini-Mental State Examination; NC, normal control; 
SD, standard deviation.
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Progression to disease
Over the period of follow-up (mean=4.54 years), of 
the 53 NC individuals with normal AD biomarkers, one 
progressed to MCI due to AD and one progressed to 
MCI not due to AD. Of the 18 NC individuals with 
AD pathologic change, two progressed to MCI due to 
AD. Of the 28 NC individuals with AD biomarkers, one 
participant died and there were no other transitions. 
Of the 41 individuals with non-AD pathologic change, 
one participant died, one progressed to MCI, and one 
progressed to vascular dementia. Of the nine MCI 
individuals with AD pathologic change, one progressed 
to AD. Of the 13 MCI individuals with AD biomarkers, 
two participants died and two progressed to AD. There 
were not enough events of progression to ascertain any 
statistically significant differences in progression between 
the groups.
Discussion
This analysis evaluated the AT(N) classification system 
in a well-characterized population from the AIBL cohort, 
including cognitively healthy NC participants as well 
as those with MCI and AD. Approximately two in five 
of the elderly NC had no evidence of abnormal AD 
biomarkers, whereas one in three had biomarker levels 
consistent with AD or AD pathological change and 
almost one in three had evidence of non-AD pathological 
change. Twenty-three percent of the NC participants 
had biomarker levels aligned with the SNAP category 
(A-(N+)), which aligns with other reports in the literature 
(3, 16).
Among NC participants, those with biomarker 
evidence of AD pathology tended to perform worse on 
composite cognitive outcome assessments and the MMSE 
compared with other biomarker groups. Participants 
with abnormal non-AD-specific biomarkers performed 
similarly to those with or without normal AD biomarkers 
across endpoints. No differences were observed across 
the four biomarker groups with respect to rate of decline 
on any outcome assessment. 
Approximately three in four participants with MCI 
or AD had biomarker levels consistent with AD or AD 
pathologic change. For MCI participants, a decrease 
in AIBL-PACC scores was observed with increasing 
abnormal biomarkers; increased abnormal biomarkers 
were also associated with increased rates of decline across 
some cognitive measures. There were not enough events 
of disease progression (i.e., NC to MCI/AD or MCI to 
AD) to draw any conclusions about the risk of disease 
progression based on the biomarker constructs.
Despite the lack of statistically significant trends, 
Figure 3. Cross-sectional performance on the six cognitive measures (A: AIBL-PACC; B: Verbal Episodic Memory; C: 
Executive Function; D: CDR Sum of Boxes; E: MMSE; F: CVLT-II LDFR) for the four contracted AT(N) groups in MCI  
AD, Alzheimer’s disease; AIBL-PACC, Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing – Preclinical Alzheimer Cognitive Composite; CDR, Clinical 
Dementia Rating; CVLT-II LDFR, California Verbal Learning Test – Second Edition; Long-Delay Free Recall; MMSE, Mini-Mental State Examination; MCI, mild cognitive 
impairment; SD, standard deviation.
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which is likely to be related to the small numbers of 
participants included, observations from the current 
study are qualitatively consistent with previous work 
showing that biomarkers of AD evident before clinical 
symptoms appear to predict cognitive deficit. In a natural 
history study classifying NC participants (N=166) with a 
two-marker construct, using Aβ-amyloid (assessed using 
amyloid PET imaging) and markers of neurodegeneration 
(hippocampus volume seen on MRI, FDG-PET), those 
with normal AD biomarkers showed improvement over 
time on a composite cognitive measure derived from 
eight neuropsychological tests, likely due to practice 
effects (15). Conversely, participants who either had 
evidence of Aβ-amyloid pathology or were considered 
SNAP participants had reduced practice effects, and 
those positive for both Aβ-amyloid pathology and 
markers of neurodegeneration showed cognitive decline 
(15). An analysis of a larger group of NC individuals from 
the AIBL cohort (N=573) also applied the two-marker 
construct, using amyloid PET as a marker of Aβ-amyloid 
pathology and hippocampal volume on MRI to assess 
neurodegeneration, and showed that amyloid-PET 
positivity conferred significant risk for cognitive decline, 
with structural evidence of neurodegeneration further 
compounding this risk (16). Applying this two-marker 
construct here in a sensitivity analysis, highlighted 
some baseline differences: individuals with abnormal 
CSF levels for Aβ-amyloid and one of the tau markers 
performed worse than participants with less biomarker 
abnormality on two of the cognition measures. No 
longitudinal differences were observed in the sensitivity 
analysis. 
The composite AT(N) system for classifying AD 
used in the present analysis separates markers of tau 
pathology from other neurodegenerative markers 
which is thought to improve specificity in terms of 
differentiating patients with AD vs. non-AD pathology. 
However, our inconclusive findings suggest that 
further study of the AT(N) classification system and its 
comparison to the two-biomarker constructs in larger 
groups of participants across the disease spectrum is 
needed.
Our construct employed CSF-based immunoassay 
measures for determining A, T, and (N) status, in 
comparison to the imaging metrics employed in the 
previous studies discussed (15, 16). The availability 
of immunoassay methodology for evaluating AD and 
neurodegeneration biomarkers could have important 
implications for clinical practice as this type of testing 
may be more widely accessible and cheaper than 
imaging-based methodologies. In turn, this potential 
for great accessibility vs. imaging methodologies may 
facilitate wider application of AT(N) classification in 
clinical trial methodology to screen more potential 
participants and further enrich study populations with 
AD biomarker-positive individuals who are most likely 
to show AD-related disease progression within the 
duration of the study. A much wider application would 
be achievable once blood biomarkers become available.
There are a number of limitations to this study, 
including the small sample size, which may preclude 
any statistically significant differences being observed. 
Further, only a small number of disease progression 
events occurred precluding any evaluations to be made 
regarding the power of the AT(N) criteria to predict 
progression to disease. The participants were volunteers 
who were not randomly selected from the community, 
and were generally well educated; thus, these findings 
might only be valid in similar cohorts and this limitation 
precludes the generalization of the findings. In view 
of the stringent selection criteria in AIBL, which 
excluded individuals with cerebrovascular disease or 
other dementias, the effect of other comorbidities on 
the trajectories might be underestimated. Longitudinal 
cognitive performance was based on three composite 
measures as well as two clinical scores and one standard 
measure, which were corrected using within-study 
norms; however, other cognitive tests, or combinations 
thereof, might yield different results. Further, biomarker 
levels were obtained from a CSF immunoassay and 
different techniques may yield different results. The cut-
offs used for dichotomous stratification were somewhat 
arbitrary and continuous variables might provide better 
predictors of progression. Another potential limitation is 
the non-specificity of t-tau for the (N) classification and 
other markers, such as neurofilament light, either in CSF 
of plasma, may provide a more robust assessment of (N). 
In conclusion, increasing CSF biomarker abnormality 
appears to be associated with worse cognitive trajectories. 
The implementation of the AT(N) classification could 
help better characterize prognosis in clinical practice and 
identify those at-risk individuals more likely to progress, 
for inclusion in future therapeutic trials. However, 
our inconclusive findings suggest that further study 
of the AT(N) classification system in larger groups of 
participants is warranted.
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